Theralase Technologies Inc. Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 25, 2021 at 07:08 am
Theralase Technologies Inc. announced that MidLantic Urology ("MU") has received site Institutional Review Board ("IRB") approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study to enroll and treat patients with Bacillus Calmette Guerin("BCG")-Unresponsive Carcinoma In-Situ ("CIS") or who are intolerant to BCG Therapy ("Study II").